Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

Warburg Pincus, a major shareholder and board member of Sotera Health, sold 9.7 million shares (22.18% of its indirect stake) for $158.7 million on December 3, 2025, at $16.33 per share. Despite the insider selling, Warburg Pincus retains over 34 million shares in the sterilization and lab services company, which has shown strong performance with 31.25% year-over-year growth and consistent earnings growth.

Darsana Capital initiated a new $189 million stake in Wingstop, purchasing 750,000 shares representing 4.45% of their portfolio. Despite recent same-store sales declines, the investment suggests potential long-term growth in the restaurant chain.

Sotera Health Company, a global provider of sterilization solutions and lab services, has appointed Vincent K. Petrella as its new Lead Independent Director, effective January 2, 2025. Petrella, who has served on the company's board since 2020, brings extensive public company leadership experience and will serve as a key liaison between the board, management, and shareholders.

Sotera Health, a leading global provider of sterilization solutions and lab testing services, will hold an Investor Day in New York City to discuss its strategic positioning and future growth plans, including a long-term financial outlook and a 2025-2027 financial plan.

The pharmaceutical sterility testing market is growing rapidly due to increasing demand for safe and effective pharmaceutical products, advancements in testing technologies, and the rising focus on biopharmaceuticals. The market is expected to reach $3.79 billion by 2032, driven by stringent regulations, the need for sterility testing in new therapies, and the shift towards in-house testing.

Sotera Health Company announced a secondary offering of 25,000,000 shares of its common stock, with all shares being offered by certain affiliates of Warburg Pincus and GTCR as selling stockholders. The company will not receive any proceeds from the offering.

Sotera Health Company, a global provider of sterilization solutions and lab services, announced plans to release its Q2 2024 financial results on August 5, 2024, followed by a conference call with management.

Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the “TLB”) as well as an issuance of senior secured notes in an aggregate principal amount of $750.0 million (the “Notes") (collectively, the “Financings”), both of which mature in 2031. The Company used the net proceeds from the Financings, along with cash on hand, to refinance its existing $1.76 billion Term Loan B and $496.3 million Term Loan B facilities.

Ratings for Sotera Health (NASDAQ:SHC) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 1 0 0 0 3M Ago 0 3 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.79, with a high estimate of $20.00 and a low estimate of $13.00. A decline of 2.67% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study An in-depth analysis of recent analyst actions unveils how financial experts perceive Sotera Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jason Bednar Piper Sandler Announces Neutral $13.00 - Luke Sergott Barclays Lowers Overweight $14.00 $19.00 Patrick Donnelly Citigroup Lowers Buy $16.00 $18.00 David Windley Jefferies Raises Buy $15.50 $15.00 Sean Dodge RBC Capital Maintains Outperform $20.00 - Sean Dodge RBC Capital Maintains Outperform $20.00 - Luke Sergott Barclays Raises Overweight $19.00 $17.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sotera Health. This insight gives a snapshot of analysts' perspectives on the current state of the company. Rating: Offering insights into predictions, analysts assign qualitative ...Full story available on Benzinga.com

SHC earnings call for the period ending March 31, 2024.